Skip to main content

Table 3 Univariate analysis via Cox- regression model of the influence of clinicopathologic variables on survival outcomes in patients with EGFR mutation receiving EGFR-TKIs

From: Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

variable

category

PFS

OS

HR (95% CI)

p-value

HR (95% CI)

p-value

Smoking history

ever-smokers vs. never smoker

1.9(1.31–2.76)

0.001

2.206(1.43–3.40)

< 0.001

Smoking dosage

never smoker (PY = 0, Ref.)

1

 

1

 

0 < PY ≤10

0.84(0.45–1.55)

0.08

0.96(0.41–2.25)

0.93

11~ 30 PY

2.95(1.76–4.94)

< 0.001

2.29(1.29–4.05)

0.004

>  30 PY

8.33(4.18–16.75)

< 0.001

4.91(2.66–9.06)

< 0.001

11~ 30 PY vs. > 30 PY

2.97(1.35–6.56)

0.007

2.22(1.08–4.57)

0.03

Age

> 60 vs. ≤ 60 years

1.05(0.72–1.53)

0.78

0.99(0.64–1.53)

0.98

Sex

Male vs. female

1.39(0.78–1.62)

0.084

1.91(1.238–2.947)

0.003

ECOG PS

≥ 2 vs 0–1

1.76(0.99–3.12)

0.05

3.12(1.73–5.62)

< 0.001

Stage

IV vs. recurrent or III

1.23(1.03–1.46)

0.02

1.4(1.1–1.9)

0.02

Type of EGFR mutation

19 del vs. 21 L858R

1.2(0.81–1.7)

0.36

0.66(0.38–1.15)

0.15

Brain metastasis

 

1.9(1.3–2.9)

0.001

2.54(1.46–4.41)

0.001

Line of targeted therapy

≥2nd line vs. 1st

1.15(0.80–1.64)

0.439

1.92(1.25–2.93)

< 0.001

Histopathology

High vs. low to moderate grade adenocarcinoma

1.17(0.81–1.69)

0.39

0.91(0.51–1.65)

0.78

Type of EGFR-TKI

 

0.95(0.75–1.18)

0.63

1.2 (0.53–2.69)

0.66

  1. Abbreviation: HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status
  2. EGFR epidermal growth factor receptor
  3. Hazard ratios and p values are adjusted for patients’ age (≥60 years vs. < 60 years), sex (female vs. male), ECOG status (PS status 0–1 vs. PS status 2–4), initial tumor stage (stage IV vs. III or recurrent), and line of EGFR-TKI (≥2nd vs. 1st line [Ref.]) in Cox-proportional hazard model